Clinical medicine profile
Dinoprostone (Prostaglandin E2)
Therapeutic agent (verify pharmacological class)
- Route
- See product SmPC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Allergic reaction to dinoprostone or related drugs
- history of asthma
- active pulmonary disease
- significant cephalopelvic disproportion
- malpresentation of fetus
- active pelvic inflammatory disease
- ruptured mem- branes.
Precautions
- Pregnancy termination can fail
- history of anaemia
- hypertension or hypotension
- cardiovascular disease
- diabetes mellitus
- renal disease
- pre-eclampsia
- uterine fibroids
- cervical stenosis
- uterine surgery
- epilepsy
- glaucoma
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Vaginally. Insert high into posterior fornix 3mg followed by another 3mg 6-8hrs later incase the labour is not established [max. 6mg]
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Review renal impairment dosing; many agents need CrCl/eGFR adjustment.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.
Use, effects & interactions
Indications
- Induction of labour
- elective abor- tion [between 12-18 wks of gestation]
- treatment of incomplete abortion
- therapeutic abortion [e.g. in cases of intra-uterine fetal death and congenital abnormalities incompatible with life]
- cervical ripening
- treatment of postpartum haemorrhage
- treatment of benign hydatidiform mole
Adverse effects
- Anaphylaxis
- bronchoconstriction
- burning eyes
- endometritis
- second-degree heart block
- urinary retention
- bradycardia
- adynamic ileus
- peripheral vasoconstriction
- tachycardia
- and increased uterine bleeding or pain
- severe and continuing abdominal or stomach pain
- double vision
- hematuria
Drug interactions
Open multi-drug checker ↗- Professional use: confirm indication, dose, duration, monitoring and patient counselling points against current Kenya STG / EML and the product SmPC.
- Document allergy status and key interactions.
Mechanism & disposition
It stimulates myometrial con- tractions in the gravid uterus.
Read complete mechanism
It stimulates myometrial con- tractions in the gravid uterus. It also facilitates cervical dilatation and softening. In addition, it stimulates the smooth muscle of the gastrointesti- nal tract, arterioles, and bronchioles. For cervical ripening, it softens the cervix and facilitates cervical dilation and effacement. It also stimu- lates collagenase secretion hence reducing the collagen network within the cervix.
Product-specific
Product-specific
See product SmPC
are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Pregnancy, lactation & diet
Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| Glandin E2 Gel 2mg | NABIQASIM INDUSTRIES (PVT.) LTD. | Gel 2mg | Unavailable |
| Glandin E 2 Tablet 3mg | Nabiqasim Industries (Pvt). Ltd. | Vaginal Tablet 3mg | Unavailable |
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.